Tempe, AZ, October 17, 2017 – SDC, a specialized data services Contract Research Organization (CRO) providing scalable clinical trial solutions via strategic partnerships, congratulates Aerie Pharmaceuticals, a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, on their recent announcement regarding the FDA Advisory Committee vote in favor of Rhopressa™ (netarsudil ophthalmic solution) 0.02%.
“We humbly congratulate Aerie Pharmaceuticals on the positive results of their FDA Advisory Committee meeting and wish them the best on the upcoming PDUFA date,” said Dale W. Usner, Ph.D., President at SDC.
For more information, please see the full and original press release dated October 13, 2017: Aerie Pharmaceuticals Announces FDA Advisory Committee Vote in Favor of Rhopressa™ (netarsudil ophthalmic solution) 0.02%.
